Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.

For decades, a diagnosis of glioblastoma – an aggressive, hard-to-treat cancer in the brain – has been a death sentence for patients. Only 3% to 5% of people who are diagnosed with this type of brain ...